Skip to main content

RheumNow Week in Review – The Heart Attack Report (11.2.18)

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

  1. Big news? Presented at #ACR18 as an abstract (L10) - small study of 29 primary Sjogrens syndrome pts - 8 Placebo vs 21 on Leflunomide + HCQ. At 24 weeks 1/9 PBO and 9/21 LEF/HCQ responded w/ ESSDAI improved > 3. Surprising, small, needs repeating https://t.co/xC4rA1JFIb
  2. CBC: neutrophil‐to‐lymphocyte ratio (NLR) and platelet‐to‐lymphocyte ratio (PLR) are significantly elevated in #RA and is as effective as CRP & ESR in correlating w/ DAS28-ESR https://t.co/K15vSHywfI https://t.co/xvqMWMqU0t
  3. Nationwide Inpatient Database (2005-2014) studied 2036 SLE patients with MI (STEMI and NonSTEMI) and showed hospital outcomes (Mortality, CABG, AE, hosp stay, costs) same as non-SLE patients. https://t.co/VpOrNh1fq0
  4. In contrast to RF, ACPA is not increased in HCV infection; among 271 HCV‐infected pts (no arthritis) they found 47% RF+, 1.1% ACPA+, 8.9% high‐positive RF, and 1.1% high‐positive ACPA. https://t.co/35wFgGVWcH
  5. Taiwan claims data shows that among 4036 psoriasis pts with HTN followed for 5.4 yrs, there was a 28% higher risk of cardiovascular procedures and surgery (aHR 1.28; 95% CI, 1.07-1.53); moreso in PsA and with severe psoriasis. https://t.co/cgpY8s3WDs
  6. Data from >50K commercial and Medicare claims in RA patients shows the risk of VTE (DVT/PE) to No different comparing pts on tofacitinib vs TNFi (HR 1.33; 95% CI, 0.78-2.24). Abst L09 #ACR18 https://t.co/dafoEcl9pD
  7. Amazing Single Center study using Methotrexate (~15/wk) prophylaxis in 10 pts starting IV pegloticase for refractory gout - ALL responded; no immunogenicity, no rise in SUA. Another way of preventing interference by anti-PEG Abs. #ACR18, Abstr #1286 https://t.co/D4oWLNYaPE
  8. Anti-phospholipid Antibodies and Myocardial Infarction   
  9. Spotlight on Interstitial Lung Disease at ACR 2018 
  10. RheumNow.Live  March 22-24, 2019 in Fort Worth Texas

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has received compensation as an advisor or consultant on this subject